Moderna shares surged approximately 55% over the past 30 days, driven by a unanimous FDA advisory committee vote backing its mRNA-based seasonal flu vaccine and a transformative Science Day presentation. The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mFLUSIVA (mRNA-1010) outweigh its risks for adults aged 50 and older, with a final regulatory decision expected by August 5, 2026.

Apogee Therapeutics (APGE) surged approximately 55% over the last 30 days, driven primarily by the announcement of a definitive acquisition agreement with AbbVie at $135.11 per share in cash. The all-cash deal values Apogee at roughly $10.9 billion and represents a substantial premium over where shares traded before the announcement.

Kymera Therapeutics shares surged approximately 32% over the past 30 days, climbing from around $85.59 on June 15 to $113.24 as of mid-July 2026. The rally was ignited by the early completion of enrollment in the Phase 2b BROADEN2 trial of lead candidate KT-621 for atopic dermatitis, nearly six months ahead of schedule.

Cytokinetics (CYTK) surged approximately 14.5% over the last 30 days, climbing from $71.38 on June 15, 2026, to $81.70 as of mid-July 2026, driven by mounting commercial momentum for Myqorzo and bullish analyst calls. Over the broader quarter, the stock gained roughly 25%, reflecting the company's successful transition into a commercial-stage biotech following the U.S. launch of its first FDA-approved drug, Myqorzo (aficamten).

Bio-Techne shares surged approximately 27% over the past 30 days, driven by Merck KGaA's announcement of an $11.3 billion all-cash acquisition at $73 per share. The acquisition offer, representing a 36% premium to Bio-Techne's one-month volume-weighted average trading price, immediately repriced the stock from the mid-$50s to above $70.

CELC plummeted -14.45% during regular trading on Wednesday, falling from Tuesday's close of $111.05 to $95.00, with selling pressure already evident in after-hours and premarket sessions. The decline follows a classic "sell the news" reaction after Tuesday's landmark FDA approval of Revtorpyk (gedatolisib) for HR+/HER2- advanced breast cancer, which had initially sent shares +6.99% higher to close at $111.05.

BeOne Medicines (ONC) surged approximately 14.3% over the last 30 days, climbing from $268.20 on June 15 to $306.56 on July 14, 2026. The rally was fueled by positive Phase 3 MANGROVE trial results, an analyst upgrade from Jefferies, and strong clinical data presentations at major oncology conferences.

BridgeBio Pharma (BBIO) surged approximately 23.7% over the last 30 days, climbing from $68.00 on June 15, 2026, to $84.09 as of July 14, 2026. A $1 billion preferred equity investment led by Sixth Street and HealthCare Royalty (a KKR business), announced July 1, signaled strong institutional confidence at a conversion price representing more than a 100% premium.

Rhythm Pharmaceuticals (RYTM) shares surged approximately 22.6% over the last 30 days, climbing from $89.70 on June 15 to $109.96 as of July 14, 2026. Multiple positive clinical data presentations at ENDO 2026, including promising six-month Phase 2 results for setmelanotide in Prader-Willi syndrome and 52-week bivamelagon data, fueled investor enthusiasm.

Mirum Pharmaceuticals (MIRM) surged approximately 19.7% over the past 30 days, climbing from $101.00 on June 15 to $120.89 on July 14, 2026. The rally was fueled by positive pivotal Phase II data for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and the FDA's acceptance of the New Drug Application (NDA) under priority review.

Immunovant (IMVT) shares climbed approximately 16% over the past 30 days, rising from $33.44 on June 15 to $38.77 on July 14, 2026. Over the last quarter, the stock surged roughly 41%, driven by overwhelmingly positive Phase 2 clinical data for lead candidate IMVT-1402 in difficult-to-treat rheumatoid arthritis.

Vaxcyte (PCVX) climbed approximately +18% over the last 30 days, rising from $47.46 to $56.21 as of July 14, 2026. The rally was fueled by a VAX-A1 Phase 1 clinical trial update for the company's Group A Strep vaccine candidate and broad-based analyst reaffirmations.

DNLI shares plunged -15.03% during regular trading on Tuesday, falling from a previous close of $26.48 to approximately $22.50 by midday, wiping out recent gains. The sell-off follows the Alzheimer's Association International Conference (AAIC) in London where CEO Ryan Watts delivered the opening plenary on July 12, triggering a classic sell-the-news reaction after the stock surged +82% over the past year into the event.

Relay Therapeutics (RLAY) surged approximately 26% over the past 30 days, climbing from around $14.81 on June 12 to $18.73 as of July 13, 2026, driven by a series of compelling clinical data readouts and analyst upgrades. The stock's rally was propelled by positive Phase 2 data for zovegalisib in vascular anomalies showing a 60% volumetric response rate, far exceeding the 11%–20% historical benchmark.

PHAT shares dropped -12.13% during Monday's regular session, falling to around $11.08 after closing at $12.61 the prior Friday, erasing nearly all gains from the prior week's rally. The decline appears driven by profit-taking following a sharp ~20% surge over the previous five sessions, with no specific negative company news or fundamental catalyst identified.

TSHA shares are down approximately -14.20% to around $5.44 during regular trading hours on Monday, extending Friday's -3.50% decline. The selloff was triggered by fallout from a pre-arranged insider sale disclosed Friday, in which the President and Head of R&D sold 200,000 shares worth ~$1.25M under a Rule 10b5-1 plan.

Q32 Bio shares are up approximately 75% in premarket trading Monday, July 13, 2026, ahead of the regular session open. The primary catalyst is clinical: the company released positive 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial evaluating bempikibart in severe and very severe alopecia areata.

SLDB shares fell -10.77% during regular market trading on July 10, dropping to $9.94 from a previous close of $11.14, as a broad small-cap biotech sell-off took hold. The primary catalyst was a macro-driven sector flush, with re-emerging inflation anxieties and rising bond yields triggering a risk-off rotation away from high-beta, pre-revenue biotech names.

GENB shares plunged -9.92% during regular trading on Thursday, falling from a prior close of $15.72 to $14.16, with no specific company news catalyst emerging in the past 24 hours. The sell-off appears to be a sharp profit-taking unwind after a recent rally fueled by the stock's inclusion in the Russell 2000 Index and steady accumulation by ARK Invest.

PRME shares fell -12.29% during regular trading to $3.71, retreating sharply from the prior close of $4.23 as profit-taking set in after a blistering rally. The stock had surged over +50% in the preceding three weeks following a July 6 arbitration victory against Beam Therapeutics that removed legal uncertainty around its lead PM647 gene-editing program.